Nephron Research analyst Chris Pasquale upgraded Boston Scientific (BSX) to Buy from Hold with an unchanged price target of $85 post the Q1 report. The company reset expectations, which “clears a path” for share outperformance, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $78 from $86 at Baird
- Boston Scientific price target lowered to $75 from $94 at Wells Fargo
- Boston Scientific price target lowered to $96 from $100 at Barclays
- Boston Scientific Balances Strong Q1 With Softer Outlook
- Boston Scientific price target lowered to $84 from $87 at Goldman Sachs